Overview
| Product name | Recombinant Human Osteoactivin/GPNMB Protein |
|---|
| Catalog No. | RP01390 |
|---|
| Description | Recombinant Human Osteoactivin/GPNMB Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Met1-Pro474) of human Osteoactivin/GPNMB (Accession #NP_002501.1) fused with a 6×His tag at the C-terminus. |
|---|
| Bio-Activity | Measured by its binding ability in a functional ELISA. Immobilized Human GPNMB Protein at 1 μg/mL (100 μL/well) can bind GPNMB Rabbit pAb with a linear range of 0.976-116.5 ng/mL.
|
|---|
| Purity | > 95% by SDS-PAGE. |
|---|
| Endotoxin | <0.1EU/μg |
|---|
| Formulation | Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4. |
|---|
| Species | Human |
|---|
| Calculated MW | 54.02 kDa |
|---|
Background
Transmembrane glycoprotein NMB (GPNMB) is also known as Transmembrane glycoprotein HGFIN, DC-HIL and Osteoactivin (OA), which belongs to the PMEL/NMB family. GPNMB contains one PKD domain.GPNMB protein acts as a downstream mediator of BMP-2 effects on osteoblast differentiation and function. GPNMB participates in bone mineralization and functions as a negative regulator of inflammation in macrophages. Osteoactivin is expressed at high levels in normal and inflammatory liver macrophages suggesting a significant role in acute liver injury. The early-phase upregulation of Osteoactivin expression in the tubular epithelium in response to renal injury might play a role in triggering renal interstitial fibrosis via activation of matrix metalloproteinase expression and collagen remodeling in rats. Osteoactivin is a protein that is expressed in aggressive human breast cancers and is capable of promoting breast cancer metastasis to bone.
Product information
| Synonym | GPNMB; HGFIN; NMB |
|---|
| Expression Host | HEK293 cells |
|---|
| Tag | C-His |
|---|
| Swiss-Prot | |
|---|
| Gene ID | |
|---|
Usage guide
| Storage | Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week. |
|---|
| Reconstitution | Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles. |
|---|
* For research use only. Not for therapeutic or diagnostic purposes.
